Literature DB >> 8620489

Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression.

B Seliger1, A Hohne, A Knuth, H Bernhard, T Meyer, R Tampe, F Momburg, C Huber.   

Abstract

In some human tumors, reduced or defective MHC class I surface expression has been attributed to functional deficiencies of the genes of the antigen-processing machinery, the proteasome subunits low molecular weight (LMP)-2 and LMP-7, as well as the peptide transporters associated with antigen processing (TAP)-1 and TAP-2. Using normal epithelial kidney cells (MZ1851NN) and renal cell carcinoma cell lines established from the primary tumor (MZ1851RC) and a lymph node metastasis (MZ1851LN) of the same patient, we investigated whether the modulation of MHC class I antigens, TAP and LMP molecules, occurs during transformation and subsequent progression. The mRNA and protein expression of MHC class I heavy and light chain TAP and LMP was strongly reduced in MZ1851RC when compared to the corresponding normal kidney cells MZ1851NN, and this suppression was even more pronounced in the metastatic cell line MZ1851LN. In addition, the activity of the TAP molecules, as measured by peptide translocation assays, was also markedly diminished in MZ1851RC compared to MZ1851NN cells and was further down-regulated in cells of the metastatic lesion. MHC class I surface expression was enhanced by either culturing MZ1851RC and MZ1851LN cells at 26 degrees C instead of 37 degrees C or by incubation of both cell lines with class I-specific binding peptides, whereas MHC class I surface expression of MZ1851NN cells was not affected under these culture conditions. IFN-alpha and in particular IFN-gamma treatment enhances the steady-state mRNA and/or protein levels of TAP, LMP, and MHC class I genes of MZ1851 cell lines but had no additional effect on the stability of MCH class I surface expression. These data indicate that malignant transformation and subsequent in vivo selection of renal tubular cells can lead to the recovery of carcinoma cells that show stable expression of an immune escape phenotype. Deficiencies associated with this phenotype involve all levels of the MHC class I-restricted antigen presentation machinery, are at least partially reversible by IFN treatment, and are even more pronounced in cells that had acquired metastatic potential.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8620489

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Interleukin-10: a cytokine used by tumors to escape immunosurveillance.

Authors:  F Salazar-Onfray
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

Review 2.  Cancer gene and immunotherapy: recent developments.

Authors:  P Jantscheff; R Herrmann; C Rochlitz
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

Review 3.  The 26S proteasome complex: an attractive target for cancer therapy.

Authors:  Sarah Frankland-Searby; Sukesh R Bhaumik
Journal:  Biochim Biophys Acta       Date:  2011-10-18

4.  Loss of expression of antigen-presenting molecules in human pancreatic cancer and pancreatic cancer cell lines.

Authors:  H Pandha; A Rigg; J John; N Lemoine
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

5.  Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma.

Authors:  Barbara Seliger; Sven P Dressler; Ena Wang; Roland Kellner; Christian V Recktenwald; Friedrich Lottspeich; Francesco M Marincola; Maja Baumgärtner; Derek Atkins; Rudolf Lichtenfels
Journal:  Proteomics       Date:  2009-03       Impact factor: 3.984

6.  Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

Authors:  Maria R Parkhurst; Cormac DePan; John P Riley; Steven A Rosenberg; Suyu Shu
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

7.  Correlation between efficacy of PSK postoperative adjuvant immunochemotherapy for gastric cancer and expression of MHC class I.

Authors:  Gentaro Ito; Hiroaki Tanaka; Masaichi Ohira; Mami Yoshii; Kazuya Muguruma; Naoshi Kubo; Masakazu Yashiro; Nobuya Yamada; Kiyoshi Maeda; Tetsuji Sawada; Kosei Hirakawa
Journal:  Exp Ther Med       Date:  2012-04-02       Impact factor: 2.447

8.  Interferon-gamma-dependent infiltration of human T cells into neuroblastoma tumors in vivo.

Authors:  Gregor S D Reid; Xiaochuan Shan; Christina M Coughlin; Wiem Lassoued; Bruce R Pawel; Leonard H Wexler; Carol J Thiele; Maria Tsokos; Jack L Pinkus; Geraldine S Pinkus; Stephan A Grupp; Robert H Vonderheide
Journal:  Clin Cancer Res       Date:  2009-10-13       Impact factor: 12.531

9.  Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses.

Authors:  Andreas Lundqvist; Andreas Palmborg; Gawa Bidla; Mike Whelan; Hardev Pandha; Pavel Pisa
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

Review 10.  Regulation of tumor growth by IFN-gamma in cancer immunotherapy.

Authors:  G L Beatty; Y Paterson
Journal:  Immunol Res       Date:  2001       Impact factor: 4.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.